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ABSTRACT
Objective: Acenocoumarol is anoral anticoagulant with narrow therapeutic index, and the ideal dose of anticoagulation lies between International 
normalized ratio (INR) values of 2.0 and 3.5. Lack of monitoring and knowledge on acenocoumarol therapy may compromise patient’s safety resulting 
in under- or over-anticoagulation. A study was conducted to monitor for the safety of anticoagulation therapy, achievement of goal INR levels and to 
assess the impact of pharmacist led anticoagulation monitoring and patient education on the rational use of acenocoumarol in patients admitted in 
cardiology wards with thromboembolic disorders.
Methods: The study was conducted in 70 patients; data collection was done, prescriptions were analyzed for drug-drug interactions and adverse 
drug reactions (ADRs). Patients’ knowledge on acenocoumarol therapy was assessed using a self-developed questionnaire at the baseline, then were 
subjected to a detailed patient education and on an average each patient received three sessions of education. They were again made to answer the 
same questionnaire on the day of discharge. The mean score of the responses before and after education was compared statistically using Wilcoxon 
signed rank test and McNemar test.
Results: There were 60% patients under anticoagulated with the INR range of >2.0. 123 drug interactions were observed in 58 patients, on an 
average of 2 interactions per prescription, but no ADRs were observed. 59 patients (84.3%) showed significant overall improvement in knowledge on 
anticoagulation therapy following education.
Conclusion: This study implies the role of clinical pharmacists in achieving better clinical outcomes in patients receiving oral anticoagulation therapy 
with acenocoumarol.
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INTRODUCTION
Oral anticoagulants have proved their efficacy in treatment or prophylaxis 
of pulmonary embolism, deep vein thrombosis, stroke, intracardiac 
clots, and atrial fibrillation for the past 60 years [1]. Worldwide, till 
today, the most commonly used Vitamin K antagonists were coumarin 
analogues warfarin and to a lesser extent acenocoumarol [2]. The 
coumarin analogues are characterized by low therapeutic index and 
interindividual treatment response variability. Hence, the dosage 
must be individualized and tapering of dosage is recommended before 
discontinuation [3]. Oral anticoagulants are associated with an increase 
hemorrhagic risk despite well-proven efficacy which can limit their use 
in older people. Warfarin and acenocoumarol work by reducing the 
effects of Vitamin K that is used by the body in the process of blood-
clotting. It inhibits Vitamin K reductase resulting in depletion of the 
reduced form of Vitamin K [4].
Depending on the clinical indication, the optimal dose of 
anticoagulation or therapeutic range to be aimed at generally lies 
between International normalized ratio (INR) values of 2.0 and 3.5. 
Higher INR values up to 4.5 may be required in individual cases [5]. 
The INR, a standardized measure used for reporting prothrombin 
time, is the recognized standard for monitoring oral anticoagulation 
therapy. All the available oral anticoagulants (warfarin, acenocoumarol 
and phenindione) have narrow therapeutic index, so monitoring is 
essential to ensure safety and effectiveness. Patient education and 
cooperation are vital during anticoagulation. A lack of knowledge 
about the therapy may compromise a patient’s safety resulting in: 
Under- or over-anticoagulation; concurrent self-administration 
of drugs that may interfere with treatment; a failure to recognize 
problems, such as bleeding, early; and the inability to manage missed 
doses [4,6].
The safe management of oral anticoagulation in patients is a challenge 
in the hospital and the community. The clinical pharmacists with 
experience can play an important role in inpatient oral anticoagulation 
management, thereby providing improved cost-effective quality of care. 
The pharmacist-managed anticoagulation program compared to usual 
care by the physicians achieved significantly better INR control, and the 
values were kept in between the range [7].
Various studies have reported the utilization patterns of warfarin as 
anticoagulation therapy. However, the use of warfarin has declined with 
the increase in the usage of acenocoumarol, whereas the extent of use 
of acenocoumarol has not been much reported in the literature [8]. 
Hence, an attempt was made to assess the drug utilization patterns 
of acenocoumarol in procoagulant disorders and the extent of 
patient’s knowledge and their medication adherence patterns to oral 
anticoagulation therapy.
METHODS
A prospective observational study was conducted in a tertiary care 
hospital for 6 months. The study included 70 patients between the age 
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groups of 21-75 years of both genders who could understand and speak 
English or local language.
The study was conducted after obtaining the approval of the 
institutional ethics committee (Ethics number CSP/14/OCT/37/213) 
and the consent of the study participants. Data on patient’s 
demographics (age, sex, educational status, and economic status) chief 
complaints, past medical and medication history, lab investigations 
(prothrombin time, INR), diagnosis, comorbidities, and coprescribed 
drugs were collected by direct history interview of the patients and 
from patients’ case sheets and documented in the proforma specially 
designed for the study. The prescriptions of the patients were assessed 
for the prescribing patterns of acenocoumarol, drug-drug interactions 
using Stockley’s drug interactions [9] and up to date database [10] and 
the causality of adverse drug reactions (ADRs) were identified using 
Naranjo’s causality assessment scale [11].
All the interactions were categorized as risk A,B,C,D and X indicating 
there was no known interaction, no action needed, monitoring of therapy, 
modification of therapy and death, respectively. The educational status 
and socioeconomic status were classified using Kuppuswamy scale into 
four classes namely Class I as illiterates; Class II as higher secondary, 
Class III as graduate, and Class IV as post graduate for the educational 
status; Class I as upper class, Class II as upper middle, Class III as lower 
middle, and Class IV as lower for economic status [12].
The study patients were assessed for their knowledge on 
acenocoumarol therapy using a questionnaire specially developed 
for the study. The questionnaire consisted of eight questions, and the 
responses were graded quantitatively as 1 for “Yes” response and 0 for 
“No” response. The patients were made to answer the questionnaire 
at the baseline and were subjected to a detailed patient education 
both verbally and by provision of patient education leaflets prepared 
specially for the study in English and vernacular language Tamil. 
Each education session lasted for around 30 minutes and was done 
till discharge (3-5 days). The patients were again made to answer the 
same questionnaire after the education session on the day of discharge. 
On an average, the patient received three sessions of education. The 
mean score of the responses obtained before and after education was 
compared for assessing the impact of patient education on knowledge 
of acenocoumarol therapy.
Statistical analysis
The data obtained were analyzed statistically using SPSS 16.0 version. 
To describe about the data descriptive statistics frequency analysis, 
percentage analysis was used for categorical variables and for 
continuous variables the mean and S.D were used. Wilcoxon signed 
rank test was used to find the significant difference in knowledge 
pre- and post-patient education. McNemar test was used and for 
comparison total score between pre- and post-patient education. In 
both the above statistical tool, the p<0.05 was considered as significant 
level. The applicability and reproducibility of the questionnaire were 
assessed statistically using Cronbach’s Alpha and a value of 0.5-0.6 was 
considered poor and above 0.6 was considered acceptable.
RESULTS
A to L of 70 patients of either sex, aged above 21 years and receiving 
oral anticoagulation with acenocoumarol were recruited from the 
wards of the cardiology unit. Of these 70 patients, 37 (52.9%) patients 
were males and 33 (47.1%) patients were females. The socioeconomic 
status and the educational status of the study patients were categorized 
into IV classes as per Kuppuswamy scale. There were 1 (1.4%) patient 
in Class I (upper); 25 (35.7%) patients in Class II (upper middle); 
21 (30%) patients in Class III (lower middle) and 23 (32.9%) patients 
in Class IV (lower) socioeconomic status. There were 43 (61.4%) 
patients in Class I (illiterates), 18 (25.7%) patients in Class II (higher 
secondary), 8 (11.4%) patients in Class III (graduate), and 1 (1.4%) 
patient in Class IV (post-graduate) educational status.
The most common indication was found to be rheumatic heart disease 
with or without mitral stenosis in 27 patients, followed by the mitral 
valve replacement in 21 patients, 8 patients had Coronary artery 
disease, 7 patients had atrial fibrillation, 2 patients had post atrial 
septal defects, and 2 patients had deep vein thrombosis. The INR 
values were within the target range of 2-3.5 for 27 (38.57%) patients, 
1 (1.42%) patient had INR value above 4.0 and 42 (60.01%) patients 
had INR values below 2.0.
In this study, of 70 patients, 123 drug interactions were observed in 
58 patients, on an average of 2 interactions per prescription. Of 123 
interactions, 7 (5.69%) interactions were under risk category D 
indicating that modification in the therapy, 59 (47.96%) interactions 
were in risk category C indicating that monitoring the therapy, 
50 (40.65%) interactions were in risk category B indicating that 
no action needed, and 7 (5.69%) interactions were in risk category 
A indicating that there was no known interaction. No ADRs were 
identified in the study population.
Patient’s knowledge on acenocoumarol therapy was assessed using a 
questionnaire specially developed for the study. The reliability of the 
questionnaire was found to be acceptable as Cronbach’s alpha value was 
found to be 0.6. The responses before education and after education 
were obtained. Table 1 explains the responses given by the study 
population for the questionnaire. Out of 70 patients, 65 responded 
“Yes” for the reason for which they were admitted in the hospital (Q1) 
which improved to 70 patients after education. Although there was an 
increase in the number of respondents, it was not statistically significant 
(p=0.063). For the Q2 on the awareness of their diagnosis, 51 responded 
“Yes” at baseline which improved to 70 patients post education and the 
improvement was found to be highly significant (p<0.0001). For the Q3 
on awareness about the drugs that they were taking at present, only 6 
responded “Yes” at baseline which improved significantly to 47 patients 
post education (p<0.0001); for Q4 about the purpose of taking the 
drug acenocoumarol 4 patients responded “Yes” at the baseline which 
significantly improved to 58 patients post education (p<0.0001); 
for Q5 stating “in case if your daily acenocoumarol dose what should 
you do?” 4 patients responded “Yes” at baseline but all 70 patients 
responded “yes” post education and the improvement was found to be 
highly significant (p<0.0001); for Q6 on “what is the purpose of INR 
testing and how frequently it has to be done?” none responded “Yes” 
at baseline but it significantly improved to 50 patients post education 
(p<0.0001); for Q7 on awareness of the possible side effects of the drug 
acenocoumarol none responded “yes” at the baseline which improved 
significantly to 47 patients after education (p<0.0001); for Q8 stating 
“Do you know whom to report if at all any side effects are observed?” 
8 patients responded “Yes” at the baseline but the responses improved 
significantly to 70 patients after education (p<0.0001).
The questionnaire was scored based on the responses given by the 
patients. A score of 1 was given for a “Yes” response and 0 was given 
for a “No” response. A mean score of 1-4 depicted “no improvement 
in knowledge,” and a mean score of 5-8 depicted “improvement in 
knowledge.” Of the total study population, 11 (157%) showed no 
improvement in knowledge and 59 (84.3%) showed improvement in 
knowledge following education.
A comparison was done between age, gender, educational status, and 
socioeconomic status with respect to the knowledge of patients about 
acenocoumarol therapy after education as shown in Table 2. There was 
a statistically significant influence of gender and socioeconomic status 
toward patients’ knowledge on acenocoumarol therapy (p=0.016 and 
p=0.004, respectively), but significant influence was not found with age 
and educational status toward patients knowledge on acenocoumarol 
therapy (p=0.561 and p=0.114, respectively).
DISCUSSION
Over the past 40 years, an outstanding progress has occurred in 
the field of oral anticoagulation therapy. New anticoagulants have 
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been introduced, new strategies have been developed for older 
anticoagulants and new indications have been identified for existing 
anticoagulants. However, most of the results referred to the treatment 
with warfarin in literature while acenocoumarol is less studied.
The challenging task of anticoagulation therapy is to attain the 
therapeutic range of INR with lowest effective dose. Lower than 
normal INR predisposes patients to thrombotic risk and higher than 
therapeutic range exposes the patients to potentially life threatening 
bleeding complications.
Various studies have shown the effectiveness of clinical pharmacist 
in anticoagulation management both in outpatient and inpatient 
settings [13]. In this study, acenocoumarol was given to the patients 
in the brand name of acitrom, at five different doses in 1 mg, 2 mg, 
3 mg, 4 mg, and 7 mg once daily for patients with various procoagulant 
disorders. The INR values were found to be within the therapeutic range 
of 2.0-3.5 only for 27 patients, whereas 42 patients had an INR of below 
two indicating that they were under anticoagulated. One patient was 
given 7 mg of acitrom and the INR value was found to be above eight due 
to severe hyper anticoagulation. The patient was treated with Vitamin K 
following which the INR value dropped and then the acitrom dose was 
tapered to 4 mg at the time of discharge. The study also observed that 
there was no relation between INR values and doses of acitrom [14].
On comparing the association of acitrom doses with INR values, only 
6 patients on 4mg of acitrom met with mean INR in the target range 
of 2-3.5. Whereas, patients on other doses of the drug had a mean INR 
range below target level. The changes in the INR values irrespective of 
doses could be due to interindividual variability of the patients.
The interaction of oral anticoagulants which coprescribed drugs and the 
variability in response from different patients makes it very difficult to 
attain and maintain the therapeutic range of INR. In this study, 123 drug 
interactions were observed between acenocoumarol and coprescribed 
drugs. The interaction between acenocoumarol and pantoprazole 
was found to be highest followed by paracetamol. The majority of 
interactions require monitoring of therapy whereas interactions with 
phenytoin, aspirin and naproxen required modification of therapy. 
Hence, they were brought to the knowledge of the physician. As 
majority of the patients where under anticoagulated, (60% patients had 
an INR value below the target range of 2.0) no side effects or adverse 
drug interactions were observed in the study population.
In this study, patients’ base line knowledge on oral anticoagulation 
therapy was found to be low, but significant improvement was observed 
following patient education. A similar study carried out by Chiquette 
et al., on “Comparison of an anticoagulation clinic with usual medical 
care” also stated that an improved anticoagulation control, decreased 
hemorrhage and thromboembolic events were achieved by the clinical 
pharmacist managed anticoagulation clinic which in turn reduced 
hospitalizations and emergency department visits for the patients [15]. 
A study conducted by Andhuvan et al. emphasized the significant impact 
of personalized continuous counseling episodes between pharmacist 
and a patient in improving their medication adherence patterns and 
promoting rational use of drugs [16].
Oral anticoagulants being high-risk medications that require regular 
monitoring, continuous multidisciplinary intervention would be 
very effective in achieving safety and efficacy in patient care. Clinical 
pharmacists can play a key role in anticoagulation management 
Table 1: Assessment of patient knowledge on acenocoumarol therapy




Are you aware of the reason for your admission in the hospital? 65 70 0.063
Do you know the name of your disease? 51 70 <0.0001**
Name the drugs you are taking at present? 6 47 <0.0001**
Do you know for what purpose acitrom has been given to you? 4 58 <0.0001**
In case if you miss your daily acitrom dose, what should you do? 4 70 <0.0001**
What is the purpose of INR testing and how frequently it has to be done? 0 50 <0.0001**
What are the possible side effects of acitrom? 0 47 <0.0001**
Do you know whom to report if at all any side effects are observed? 8 70 <0.0001**
**A p<0.01 was considered as highly significant
Table 2: Baseline characteristics versus patients’ knowledge on acenocoumarol therapy
Characteristic Outcome of education Significance p
No improvement (%) Improvement (%)
Age range
21-40 4 (36.4) 11 (18.64) 0.561
41-60 4 (36.4) 27 (45.76)
>60 3 (27.3) 21 (35.59)
Gender
Male 7 (63.6) 30 (50.84) 0.016
Female 4 (36.4) 29 (49.15)
Educational status
Class I (illiterate) 5 (45.5) 38 (64.4) 0.114
Class II (higher secondary) 3 (27.3) 15 (25.42)
Class III (graduate) 2 (18.2) 6 (10.16)
Class IV (post graduate) 1 (9.1) 0 (0)
Socioeconomic status
Class I (upper) 1 (9.1) 0 (0) <0.01**
Class II (upper middle) 4 (36.4) 21 (35.59)
Class III (lower middle) 3 (27.3) 18 (30.50)
Class IV (lower) 3 (27.3) 20 (33.89)
**A p value of <0.01 was considered highly significant
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by providing structured patient education to improve medication 
adherence, regular monitoring of therapy for drug-drug interaction and 
ADR for making necessary interventions. In accordance to this, the study 
conducted by Ibrahim et al. also indicated that patients who received 
intensive counseling from clinical pharmacists showed significantly 
better understanding than the “usual medical care” group. It is further 
evident from this study that Pharmacists can play an important role 
in managing anticoagulation therapy through continuous patient 
education on appropriate drug use and adherence which will be very 
effective in minimizing drug-related problems and achieving patient 
satisfaction [17].
CONCLUSION
Patients’ knowledge on oral anticoagulation drug usage is crucial for 
innocuous and effective use of oral anticoagulation therapy. Awareness 
on INR ranges, monitoring requirements, drug - drug interactions and 
adverse reactions is vital for patients since a positive relationship exists 
between their knowledge and outcomes of the therapy. The present 
study highlights the effect of patient education on improvement of 
patient’s knowledge on oral anticoagulation therapy and the overall 
therapeutic outcome of patients on acenocoumarol. The target range 
of INR was achieved in 40% of the patients. The study suggests that a 
clinical pharmacist driven anticoagulation service can aid patients to 
achieve a significant therapeutic outcome and also assist the physicians 
to provide better patient care with added safety.
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